beta-funaltrexamine

RN given refers to parent cpd(E)-isomer; structure given in first source

Also Known As:

beta-FNA; beta-funaltrexamine monohydrochloride, (E)-isomer; naltrexone fumarate methyl ester; 2-Butenoic acid, 4-(((5alpha,6beta)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl)amino)-4-oxo-, methyl ester, (E)-

Networked: 63 relevant articles (2 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Sun, Yan-Gang: 3 articles (08/2007 - 07/2003)
2.	Yu, Long-Chuan: 3 articles (08/2007 - 07/2003)
3.	Tang, Jing-Shi: 2 articles (10/2008 - 03/2006)
4.	Wang, Jun-Yang: 2 articles (10/2008 - 03/2006)
5.	Zhao, Mei: 2 articles (10/2008 - 03/2006)
6.	Buck, Daniel J: 2 articles (09/2008 - 05/2007)
7.	Davis, Randall L: 2 articles (09/2008 - 05/2007)
8.	Saffarian, Neda: 2 articles (09/2008 - 05/2007)
9.	Stevens, Craig W: 2 articles (09/2008 - 05/2007)
10.	Hu, De-yao: 2 articles (11/2005 - 03/2004)

Related Diseases

1.	Hyperphagia (Overeating) 09/01/1997 - "The mu antagonist beta-funaltrexamine produced a similar pattern of effects on mu-mediated hyperphagia. " 06/01/1991 - "DALCE (10 micrograms) hyperphagia (2-10 h) was eliminated by central pretreatment with either naltrexone (20 micrograms) or the kappa antagonist, nor-binaltorphamine (20 micrograms) but was minimally affected by central pretreatment with the mu antagonist, beta-funaltrexamine (20 micrograms) or long-term DALCE (40 micrograms). " 06/01/1995 - "2-Deoxy-D-glucose hyperphagia was significantly reduced only after 2 h by naltrexone (10 micrograms, 260 nmol, 69%), norbinaltorphamine (20 micrograms, 272 nmol, 69%) or beta-funaltrexamine (20 micrograms, 400 nmol, 83%) in the paraventricular nucleus. " 05/03/1991 - "The irreversible mu opioid antagonist, beta-funaltrexamine (B-FNA, 20 micrograms, i.c.v.) significantly inhibited insulin hyperphagia by 28-54% over the 6-h time course. " 11/27/1995 - "Ventricular microinjection studies found that whereas mu (beta-funaltrexamine, B-FNA), mu1 (naloxonazine) and kappa (nor-binaltorphamine, Nor-BNI) opioid receptor antagonists, but not delta antagonists, reduce deprivation-induced intake, kappa and mu, but not mu1 or delta antagonists reduce both 2-deoxy-D-glucose (2DG) hyperphagia and sucrose intake. "
2.	Neuroinflammatory Diseases 09/01/2008 - "Further characterization of the novel, anti-inflammatory actions of beta-FNA may provide insights for pharmacologic strategies to treat or prevent brain pathologies associated with neuroinflammation." 05/01/2007 - "Understanding the mechanism by which chemokine expression is suppressed, particularly by the opioid antagonist, beta-FNA, may provide insights into the development of safe and effective treatments for neuroinflammation." 01/25/2023 - "Previous work indicated pretreatment with beta-funaltrexamine (β-FNA), a selective mu-opioid receptor (MOR) antagonist, inhibited inflammatory signaling in vitro in human astroglial cells, as well as lipopolysaccharide (LPS)-induced neuroinflammation and sickness-like-behavior in mice. "
3.	Fistula 11/25/1996 - "The present study examined whether centrally administered general (naltrexone: 1-50 micrograms), mu (beta-funaltrexamine: 1-20 micrograms), mu 1 (naloxonazine: 50 micrograms), kappa 1 (nor-binaltorphamine: 1-20 micrograms), delta 1 ([D-Ala2, Leu5, Cys6]-enkephalin: 10-40 micrograms) or delta 2 (naltrindole isothiocyanate: 20 micrograms) opioid subtype antagonists altered either maltose dextrin (10%) intake during sham feeding or deprivation (24 h)-induced water intake during sham drinking in rats with gastric fistulas. "
4.	Hyperalgesia 10/15/1991 - "Pretreatment of rats with beta-FNA (3 or 10 micrograms at -24 h), which by itself caused some hyperalgesia, greatly antagonized the antinociceptive effect of morphine (10 micrograms i.c.v.) in the hot-plate test. " 03/01/2015 - "IT pretreatment with MOR antagonist, beta-funaltrexamine (β-FNA), attenuated IT EM-2 analgesia on both thermal hyperalgesia and inflammatory pain in OVX rats. " 02/20/2004 - "However, nor-BNI could not block the EA effects on mechanical allodynia, whereas beta-FNA or naltrindole significantly blocked EA effects. " 04/12/2016 - "While the anti-hyperalgesia on thermal stimuli induced by FA was blocked by pre-treatment with 5-HT1A receptor antagonist WAY-100635, or with the irreversible mu-opioid receptor antagonist beta-funaltrexamine. " 01/01/1991 - "Patterns of morphine hyperalgesia (1.25 to 5.0 mg/kg IM) were examined on a standard hot-plate test following administration (10 micrograms/5 microliters ICV) of the mu antagonist beta-funaltrexamine, the delta antagonist naltrindole, or the kappa antagonist nor-binaltorphimine in 15-day-old White Leghorn cockerels. "
5.	Body Weight (Weight, Body) 03/01/2006 - "beta-FNA did not alter body weight or 20-h consumption of standard chow or water. " 07/01/1986 - "Animals given beta-FNA did not differ from controls in body weights, brain and cerebellar weights, macroscopic dimensions of the brain, the area of the cerebellum, or in organ weight. " 05/01/1992 - "Treatment with beta-FNA significantly diminished naloxone-induced escape behavior, hypothermia, and loss of body weight in a dose-dependent manner, while naloxone-induced teeth-chattering, forepaw tremors, and urination were also reduced, but in a dose-independent manner. " 05/01/1987 - "In addition, selective opiate antagonists (beta h-END-[6-31], a peptide beta-END antagonist [5 nmol, i.c.v.], beta-funaltrexamine [beta-FNA], an mu 1 receptor antagonist [4.8 nmol, i.c.v.], Mr 1,452 MS and Mr 2,266 BS, two kappa-receptor antagonists [10 mg/kg body weight, i.p.], ICI 154, 129, a delta-receptor antagonist [100 nmol, i.c.v.]) were administered prior to footshock stress. " 01/01/1997 - "Body weight and food intake are significantly reduced in rats during development of dietary obesity following chronic central administration of mu (beta-funaltrexamine, BFNA), mu1 (naloxonazine), kappa1 (nor-binaltorphamine, NBNI), delta1 ([D-Ala2,Leu5,Cys6]-enkephalin, DALCE) and delta2 (naltrindole isothiocyanate, NTII) opioid receptor subtype antagonists. "

Related Drugs and Biologics

1.	Narcotic Antagonists (Opioid Antagonists)
2.	Naltrexone (ReVia)
3.	Chemokines
4.	Ala(2)-Cys(6)- enkephalin-Leu
5.	naloxonazine
6.	naltrindole
7.	norbinaltorphimine
8.	Enkephalins
9.	Opioid Analgesics (Opioids)
10.	Deoxyglucose (2 Deoxy D glucose)

Related Therapies and Procedures

1.	Analgesia
2.	Ligation
3.	Spinal Injections
4.	Injections
5.	Induced Hyperthermia (Thermotherapy)